Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2022 Dec;29(13):8037-8043. doi: 10.1245/s10434-022-12238-0. Epub 2022 Aug 11.
The growing use of postmastectomy radiation/regional nodal irradiation (PMRT) has resulted in many women receiving both axillary dissection (ALND) and PMRT, increasing lymphedema rates. After developing standardized PMRT criteria, we adopted a policy of ALND omission among cN0 patients with 1-2 positive sentinel nodes (+SLNs) requiring PMRT. We evaluated how often overtreatment with ALND+PMRT was avoided with this approach.
A retrospective review of a prospectively maintained database was performed beginning 1 year before policy adoption. Intraoperative SLN evaluation was routine pre- and post-policy. ALND was performed for SLN macrometastasis pre-policy, and selectively performed post-policy for 1-2 +SLNs based on PMRT criteria. ALND+PMRT was required for ≥ 3 +SLNs.
From March 1, 2018 to November 30, 2020, a total of 2207 cT1-3N0 patients had mastectomy and 231 had +SLNs; 109 (47%) were treated pre-policy and 122 (53%) post-policy. Most (81%) had 1-2 +SLNs. There was no change in rates of ALND+PMRT (64% pre-policy vs. 58% post-policy, p = 0.09), including in patients with 1-2 +SLNs (61% vs. 51%, p = 0.20). Post-policy, ALND was omitted in 9 (7%) patients recognized intraoperatively as PMRT candidates; avoidable ALND was performed in 40 (33%) patients not identified as PMRT candidates until receipt of final pathology. Overall, had intraoperative SLN evaluation been deferred, only 5.7% of patients would have required completion ALND: 2.2% (n = 49/2207) for ≥ 3 +SLNs and 3.5% (n = 77/2207) for 1-2 +SLNs without PMRT indication.
Most patients could have avoided ALND+PMRT if decision making was deferred until final pathology was available. Selective intraoperative SLN evaluation in cN0 patients having upfront mastectomy may reduce avoidable overtreatment.
随着乳腺癌术后放疗/区域淋巴结照射(PMRT)的广泛应用,许多女性接受了腋窝清扫术(ALND)和 PMRT,导致淋巴水肿的发生率增加。在制定了标准化的 PMRT 标准后,我们对需要 PMRT 的 1-2 个前哨淋巴结(+SLN)阳性的 cN0 患者,制定了在 ALND 中排除的政策。我们评估了采用这种方法避免过度治疗 ALND+PMRT 的频率。
回顾性分析了一项前瞻性维护的数据库,该数据库在采用该政策前 1 年开始。术中 SLN 评估是术前和术后的常规检查。在该政策实施前,SLN 宏转移患者行 ALND,在该政策实施后,根据 PMRT 标准,选择性地对 1-2 个+SLN 行 ALND。≥3 个+SLN 需要行 ALND+PMRT。
从 2018 年 3 月 1 日至 2020 年 11 月 30 日,共有 2207 例 cT1-3N0 患者接受了乳房切除术和 231 例 SLN 阳性患者;其中 109 例(47%)在该政策实施前治疗,122 例(53%)在该政策实施后治疗。大多数(81%)患者有 1-2 个+SLN。ALND+PMRT 的比率没有变化(该政策实施前为 64%,该政策实施后为 58%,p=0.09),包括 1-2 个+SLN 的患者(该政策实施前为 61%,该政策实施后为 51%,p=0.20)。该政策实施后,有 9 名(7%)患者术中被识别为 PMRT 候选者,而无需行 ALND;40 名(33%)患者直到收到最终病理结果才被识别为 PMRT 候选者,这些患者未行 ALND。总体而言,如果推迟 SLN 术中评估,只有 5.7%的患者需要完成 ALND:2.2%(n=49/2207)为≥3 个+SLN,3.5%(n=77/2207)为 1-2 个+SLN 且无 PMRT 指征。
如果将决策推迟到获得最终病理结果后,大多数患者可以避免 ALND+PMRT。对行乳房切除术的 cN0 患者选择性地进行术中 SLN 评估,可能会减少不必要的过度治疗。